The exercise effects on cardiotoxicity in breast cancer patients receiving anthracycline based chemotherapy

Completed

• Conditions: 30 primary breast cancer patient receiving anthracycline chemotherapy; breast cancer, anthracycline, cardiotoxicity, exercise

• Registration Number: TCTR20190330002
• Lead Sponsor: 6F, No.35, Siao-Dong Road, Tainan, 704, Taiwan, R.O.C

Brief Summary

This study revealed that moderate-to-high intensity exercise training in breast cancer patients undergoing chemotherapy prevents impairment of cardiac function and improves exercise capacity.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-03-30
• Study Completion: 2019-08-30
• Results First Posted: 2021-01-13
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

(1)30-65 years old diagnosed with primary breast cancer, (2)breast cancer stage I-III without receiving radiotherapy and target therapy, (3)scheduled for chemotherapy with anthracycline (e.g.doxorubicin, epirubicin), (4)able to follow exercise protocol

Exclusion Criteria

(1) acute infectious disease, (2) severe neurological, respiratory and renal deficiencies, (3) severe cardiac or cardiovascular disease (e.g. LVEF<50%), (4) other concurrent malignant disease, (5) life expectancy<6 months, (6) enrolled in studies involving exercise training, (7) unable to walk or stand, (8) ongoing pharmacological cardio-protection

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
cardiac function of left ventricle ejection fraction before, 3 months and 6 months after chemotherapy echocardiography

Secondary Outcome Measures

Name	Time	Method
exercise capacity of maximal oxygen uptake before, 1.5 months, 3 months and 6 months after chemotherapy cardiopulmonary exercise test